Alzinova ABFRA:78D -2.61%21 PB Ratio is 0.33 as of Jul. 07, 2026, which is 68% below its 10-year median of 1.04. GuruFocus rates FRA:78D with a GF Score™ of 21/100. The stock has 1 warning sign investors should review. Among 1,226 Biotechnology companies, Alzinova AB ranks better than 94.94% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-07), Alzinova AB's share price is €0.0298. Alzinova AB's Book Value per Share for the quarter that ended in Mar. 2026 was €0.09. Hence, Alzinova AB's PB Ratio of today is 0.33.
The historical rank and industry rank for Alzinova AB's PB Ratio or its related term are showing as below:
FRA:78D'
s PB Ratio Range Over the Past 10 Years
Min: 0.29 Med: 1.04 Max: 2.68
Current: 0.51
During the past 10 years, Alzinova AB's highest PB Ratio was 2.68. The lowest was 0.29. And the median was 1.04.
FRA:78D's PB Ratio is ranked better than 94.94% of 1226
companies
in the Biotechnology industry
Industry Median: 2.91
vs FRA:78D: 0.51
During the past 12 months, Alzinova AB's average Book Value Per Share Growth Rate was -27.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -23.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -25.10% per year.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Alzinova AB was 22.30% per year. The lowest was -30.10% per year. And the median was -15.10% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Alzinova AB PB Ratio Related Terms
Alzinova AB PB Ratio Historical Data
* Premium members only.
The historical data trend for Alzinova AB's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Alzinova AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alzinova AB PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alzinova AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where Alzinova AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Alzinova AB's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Alzinova AB (FRA:78D) has a PB Ratio of 0.33 as of Jul. 07, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Alzinova AB and its competitors. This is 68% below median its historical median of 1.04. Over the past decade, Alzinova AB's PB Ratio has ranged from 0.29 to 2.68. According to the industry distribution chart, Alzinova AB ranks #62 out of 1226 companies in the Biotechnology industry, placing it in the top 5.1%.
Is Alzinova AB's PB Ratio too high?
Alzinova AB's current PB Ratio of 0.33 is 68% below median its 10-year median of 1.04. Over the past 10 years, this metric has ranged from a low of 0.29 to a high of 2.68. The Biotechnology industry median PB Ratio is 2.91. Alzinova AB's value of 0.33 is 88.7% below this industry median. Based on the distribution chart, Alzinova AB ranks #62 out of 1226 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Alzinova AB has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Alzinova AB's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alzinova AB ranks #62 out of 1226 companies for PB Ratio. This places Alzinova AB in the top 5% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.91. Alzinova AB's value of 0.33 is 88.7% below this benchmark. Historically, Alzinova AB's own PB Ratio has ranged from 0.29 to 2.68 over the past decade. While the company's 10-year median is 1.04 vs. the industry median of 2.91, Alzinova AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.91, based on 1,226 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alzinova AB's current PB Ratio of 0.33 is 88.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Alzinova AB and its competitors. For the Biotechnology industry, the median PB Ratio is 2.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alzinova AB's current PB Ratio is 0.33, which is 68% below median its own 10-year median of 1.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alzinova AB stock overvalued right now?
Alzinova AB (FRA:78D) has a current PB Ratio of 0.33. The current PB Ratio is 0.33, which is 68% below median its 10-year median of 1.04 and 88.7% below the Biotechnology industry median of 2.91. Alzinova AB's overall GF Score™ is 21/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Alzinova AB (FRA:78D), the current PB Ratio is 0.33 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alzinova AB is a Swedish biotechnology company engaged in the discovery and development of therapeutics for the treatment of Alzheimer's disease. The company is developing ALZ-101, an oligomer-specific therapeutic vaccine currently advancing toward Phase 2 clinical development, and ALZ-201, a monoclonal antibody targeting toxic amyloid-beta (AB) oligomers, which is in preclinical development. The company's proprietary ABCC peptide technology is focused on disease-modifying treatments for Alzheimer's disease.
21GF Score
Get the complete analysis for FRA:78D
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:78D has been successfully added to your 
